What medications are recommended for treating insomnia in patients with Chronic Kidney Disease (CKD)?

Medications for Insomnia in CKD

Direct Recommendation

For patients with CKD and insomnia, start with sleep hygiene measures and exercise programs, then consider ramelteon 8 mg for sleep-onset insomnia or low-dose doxepin 3-6 mg for sleep-maintenance insomnia as first-line pharmacotherapy, while explicitly avoiding trazodone due to significantly increased cardiovascular adverse events in this population. 1

---

Treatment Algorithm for CKD Patients

Step 1: Non-Pharmacologic Interventions (Always Start Here)

• Implement sleep hygiene measures as the first-line treatment, including addressing concurrent CKD symptoms that disrupt sleep (uremic pruritus, restless legs, nocturia) 1

• Prescribe exercise programs, which have demonstrated efficacy in improving sleep quality specifically in hemodialysis patients 1

• Optimize dialysis timing and adequacy to minimize sleep disruption in patients on dialysis 1

• Screen for and treat depression, which may require specific antidepressant treatment rather than sedatives alone 1

---

Step 2: First-Line Pharmacotherapy (When Non-Pharmacologic Measures Insufficient)

For Sleep-Onset Insomnia:

• Ramelteon 8 mg at bedtime is the optimal choice, with zero addiction potential and minimal drug interactions 1, 2
• This medication avoids respiratory depression and has no significant renal dose adjustment requirements 2

For Sleep-Maintenance Insomnia:

• Low-dose doxepin 3-6 mg is the preferred option, working through H1 histamine receptor antagonism with minimal CNS depression and no respiratory effects 1, 2
• This dose is far below antidepressant dosing and has minimal anticholinergic effects 3

---

Step 3: Alternative Pharmacotherapy (If First-Line Fails)

• Short-intermediate acting benzodiazepine receptor agonists (BZRAs) may be considered with extreme caution:

  • Zolpidem 5-10 mg (start at 5 mg) 1
  • Eszopiclone 1-2 mg (start at 1 mg) 1
  • Temazepam 7.5-15 mg (start at 7.5 mg) 1

• Critical caveat: Start with the lowest effective dose and uptitrate cautiously due to altered pharmacokinetics in CKD 1

• Gabapentin 100-300 mg at night may be considered if there is a neuropathic component to insomnia, but requires significant dose adjustment based on GFR 1

---

Medications to EXPLICITLY AVOID in CKD

Absolutely Contraindicated:

• Trazodone - Associated with significantly higher rates of serious cardiovascular adverse events in hemodialysis patients (annualized cardiovascular SAE rate 0.64 vs 0.21 for placebo) 1, 4
• This is the most important contraindication based on the highest quality recent evidence 4

Not Recommended:

• Over-the-counter antihistamines (diphenhydramine) - Lack of efficacy and safety data in CKD patients 1
• Melatonin supplements, valerian, L-tryptophan - Insufficient evidence in CKD patients 1
• Tiagabine - Specifically not recommended for insomnia in CKD 1
• Atypical antipsychotics (quetiapine, olanzapine) - Insufficient evidence and significant metabolic side effects 3

---

Critical Implementation Principles for CKD

• Monitor for QT prolongation and drug interactions when prescribing any sedative-hypnotics 1

• Follow patients every few weeks initially to assess effectiveness and adverse effects 1

• Use the lowest effective dose for the shortest duration possible with regular reassessment of continued need 1

• Adjust doses based on GFR - CKD patients have altered pharmacokinetics requiring dose reduction for most medications 1

---

Special Considerations for Dialysis Patients

• The 2024 randomized clinical trial in hemodialysis patients showed no superiority of CBT-I or trazodone over placebo for mild-to-moderate insomnia, with trazodone showing significantly higher cardiovascular adverse events 4

• This represents the single most recent and highest quality study specifically in the dialysis population, fundamentally changing recommendations away from trazodone 4

• Exercise programs remain one of the few interventions with demonstrated efficacy in this specific population 1

---

Common Pitfalls to Avoid

• Do not use trazodone despite its common off-label use for insomnia - the evidence in CKD patients shows harm 1, 4

• Do not assume standard dosing - always start lower and titrate more slowly than in patients with normal renal function 1

• Do not overlook treatable CKD-related sleep disruptors - uremic symptoms, restless legs syndrome, sleep apnea, and dialysis timing all contribute to insomnia 5, 6, 7

• Do not skip non-pharmacologic interventions - they remain first-line even though evidence for CBT-I specifically in dialysis patients is limited 1, 4